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Epidemiology of early-onset obesity
Childhood  obesity  is  one  of  the  most  serious  public 
health challenges of the 21st century. This global health 
problem  is  gradually  affecting  both  developed  and 
develop  ing  countries,  particularly  in  urban  settings.  In 
the United States, childhood overweight and childhood 
obesity are defined as a body mass index (BMI; (Weight 
in kg)/(Height in m)²) greater than or equal to the 85th 
and 95th percentile for gender and age, respectively [1]. 
In Europe, the European Children Obesity Group defined 
childhood  overweight  and  childhood  obesity  as  a  BMI 
greater than or equal to 90th percentile to 97th percentile 
for gender and age [2]. A reference population has been 
established to propose an international standard defini­
tion for childhood overweight and childhood obesity [3]. 
The prevalence of overweight and obesity in childhood is 
increasing worldwide at an alarming rate: today, about 
one in three children and adolescents is overweight or 
obese in the United States; over the past three decades, 
the  prevalence  of  obesity  has  tripled  for  children  2  to 
5  years  old  and  youths  12  to  19  years  old,  and  has 
quadrupled for children 6 to 11 years old [4]. According 
to  the  World  Health  Organization  and  to  the  Inter­
national  Obesity  Task  Force,  more  than  155  million 
children and adolescents worldwide are overweight and 
40 million are clearly obese.
Early­onset  obesity  is  associated  with  an  increased 
incidence of adult obesity [5], type 2 diabetes [6], non­
alcoholic  fatty  liver  disease  [7]  and  cardiovascular  risk 
factors  [8].  Obese  children  have  an  increased  risk  of 
develop  ing obesity­related co­morbidities, such as ortho­
pedic,  ophthalmologic  and  renal  complications  [9], 
respira  tory diseases such as obstructive sleep apnea [10], 
and  psychosocial  impairment  [11].  Obesity­associated 
complications are now believed to be leading, for the first 
time in modern history, to a decrease in life expectancy 
of 2 to 5 years for the US generation that is currently 
young [12].
Today,  medical  and  behavioral  interventions  as 
treatment  for  obesity  in  childhood  remain  scarce  and 
largely ineffective. There are currently three main treat­
ment  modalities  for  obesity:  lifestyle  modifications, 
pharmacotherapy and bariatric surgery. The cornerstone 
of lifestyle modifications includes changes to dietary and 
exercise habits [13]. However, less than 5% of the obese 
people  who  follow  these  recommendations  effectively 
lose weight and maintain that weight loss [14]. The long­
term safety and efficacy of the anti­obesity drugs (orlistat 
and sibutramine) have not been determined in children 
or adolescents, mainly because pharmacotherapy is not 
routinely proposed as a treatment for childhood obesity 
[15].  Bariatric  surgery  is  a  new  treatment  for  morbid 
obesity  in  children  but  the  relevance  of  an  invasive 
surgery  procedure  in  childhood  or  adolescence  is  still 
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case  of  laparoscopic  sleeve  gastrectomy  successfully 
performed in a 6­year­old morbidly obese child. Because 
of  the  lack  of  efficiency  of  the  current  approaches  to 
reverse childhood obesity, prevention was proposed as 
the  first  line  of  treatment  in  2003  by  the  American 
Academy of Pediatrics [18]. In its policy statement, the 
Academy promoted breastfeeding, healthy eating habits 
and  physical  activity  and  encouraged  limitation  of 
television  viewing.  However,  current  prevention  pro­
grams have had little success and have proven ineffective 
in  reversing  the  rising  rates  of  childhood  obesity  [19]. 
These disappointing observations reveal the urgent need 
to  better  understand  the  complex  molecular  and 
physiologic  mechanisms  involved  in  human  obesity  in 
order to propose better disease prevention and care.
Early-onset obesity is a heritable disorder
The epidemic of obesity is attributed to recent environ­
mental  changes.  Easy  access  to  high­energy  palatable 
food, combined with decreased physical activity levels, 
have undoubtedly had a major role in the global increase 
in the prevalence of early­onset obesity [20]. Beyond ‘the 
big two’, other putative environmental contributors to the 
recent obesity epidemic have been proposed, such as an 
obesity­prone  intrauterine  environment,  assortative 
mating among obese individuals, decreasing sleep dura­
tion,  infections  and  low­grade  inflammation  or  the 
increasingly controlled ambient temperature [21]. How­
ever, if these factors are responsible for the global shift in 
BMI distribution, genetic factors must explain most of 
the inter­individual differences in obesity risk observed 
in populations (in other words, where each individual sits 
on the BMI distribution) [22]. In fact, the risk of obesity 
in a child is ten times higher if both parents are obese 
than if both parents are of normal weight [23].
Heritability  represents  the  proportion  of  phenotypic 
variation in a population that is attributable to genetic 
variation  among  individuals.  According  to  twin  and 
family  studies,  heritability  estimates  for  BMI  during 
childhood  or  adolescence  are  between  0.20  and  0.86 
[22,24­29]. Longitudinal studies have demonstrated that 
heritability estimates tend to increase from childhood to 
pre­adolescence  [26,29]  and  from  pre­adolescence  to 
adolescence [27], probably because individuals at genetic 
risk for obesity increasingly select ‘obesogenic’ environ­
ments  (environments  that  promote  gaining  weight) 
correlated  with  their  genetic  propensities.  In  addition, 
physical activity reduces the influence of genetic factors 
on BMI in young adults, and it is likely that these results 
are transposable to children or adolescents [30]. Even if 
heritability estimations of BMI are similar in boys and 
girls,  some  sets  of  genes  explaining  the  BMI  variation 
may, at least in part, be different in males and females 
[24].  The  values  of  heritability  for  BMI  in  childhood 
remain high even in the obesogenic environment currently 
present in developed countries such as the US [22,28].
Monogenic forms of early-onset obesity
Several single­gene disorders result in severe, early­onset 
obesity.  These  monogenic  forms  of  early­onset  obesity 
show  the  biological  importance  of  the  mutant  gene  in 
body­weight control. The main genes affected in these 
monogenic  disorders  (leptin  (LEP),  leptin  receptor 
(LEPR),  pro­opiomelanocortin  (POMC),  prohormone 
conver  tase 1 (PCSK1), melanocortin 4 receptor (MC4R), 
brain­derived  neurotrophic  factor  (BDNF)  and  neuro­
trophic tyrosine kinase receptor type 2 (NTRK2)) encode 
hormones or neurotransmitters and their hypothalamic 
receptors  of  the  highly  conserved  leptin­melanocortin 
pathway, which is critical for the regulation of food intake 
and body weight [31]. A case of Single­minded homolog 1 
(SIM1)  haploinsufficiency  has  been  reported  in  one 
patient  with  early­onset  obesity  [32].  The  SIM1  gene 
encodes a transcription factor essential for formation of 
the supraoptic and paraventricular (PVN) nuclei of the 
hypothalamus.  Additional  evidence  of  a  role  of  SIM1 
haploinsufficiency in human obesity was provided by the 
finding  of  rare  non­synonymous  SIM1  mutations  en­
riched in severely obese patients in comparison with lean 
individuals  [33].  Recent  data  have  linked  SIM1  haplo­
insufficiency with Mendelian obesity and a Prader­Willi­
like syndrome (F Stutzmann et al., personal communi­
cation).  The  loss  of  function  C256Y  mutation  in  the 
wingless­type  MMTV  integration  site  family,  member 
10B (WNT10B) gene, which encodes a signaling protein 
that negatively regulates adipocyte differentiation as part 
of the Wnt signaling pathway, was shown to co­segregate 
with overweight or obesity in one pedigree, but further 
studies are needed to confirm the link between this gene 
and monogenic early­onset obesity [34].
The majority of genes involved in monogenic forms of 
early­onset obesity were identified as candidate genes on 
the basis of previous evidence from physiological studies 
and animal models. Children with a strong family history 
of obesity and issued from consanguineous families are of 
particular  interest  for  genetic  diagnosis  of  early­onset 
obesity. Monogenic obesity forms are frequently accom­
panied by additional clinical features (for example, severe 
hyperphagia,  intestinal  troubles)  and  normal  develop­
ment, except for BDNF, SIM1 and NTRK2 deficiencies, 
which  are  associated  with  cognitive  impairment, 
behavioral problems or syndromic features [35,36].
The  focus  on  the  leptin­melanocortin  pathway  as  a 
target for pharmacological intervention in patients with 
severe  obesity  turned  out  to  be  effective.  The  best 
illustration is certainly the case of a child with congenital 
leptin  deficiency  who  was  treated  with  subcutaneous 
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correction  of  all  the  phenotypic  abnormalities  seen  in 
this patient [37].
Syndromes that include early-onset obesity
Complex  obesity  syndromes  are  defined  as  Mendelian 
disorders with obesity as a clinical feature that are also 
associated with mental retardation, dysmorphic features 
and organ­specific developmental abnormalities. Over 30 
syndromes that include obesity have been identified but 
only some of them, such as the WAGR (Wilm’s tumor, 
aniridia, genitourinary anomalies and mental retardation) 
[38],  Prader­Willi  [39],  Bardet­Biedl  [40],  Alström  [41] 
and Cohen [42] syndromes, have been associated with 
early­onset obesity.
The genetic basis for these syndromic forms of early­
onset obesity has been elucidated, revealing an important 
genetic  heterogeneity.  Molecular  genetic  analyses  of 
individuals with WAGR syndrome have revealed that the 
Wilm’s tumor 1 (WT1) and Paired box 6 (PAX6) genes 
are  involved  with  this  syndrome,  but  deletions  in  the 
BDNF gene were recently shown to explain the pheno­
type of obesity found in a subgroup of patients with the 
WAGR  syndrome  [38].  Prader­Willi  syndrome  (PWS) 
can have several etiologies but it is always associated with 
loss  of  expression  of  paternally  transmitted  genes  on 
15q11­13. A microdeletion of the HBII­85 small nucleo­
lar  RNAs  (snoRNAs)  caused  the  PWS  phenotype  in  a 
child [43] and recently another de novo microdeletion at 
chromosome  15q11­13  that  encompasses  non­coding 
snoRNAs was identified in a patient affected with hyper­
phagia,  early­onset  obesity,  hypogonadism  and  mild 
learn  ing difficulties but diagnosed negative for PWS [44]. 
Bardet­Biedl  syndrome  (BBS)  has  extensive  genetic 
hetero  geneity and so far 14 genes have been associated 
with it [40]. The BBS proteins are implicated in the func­
tion  of  primary  cilia  and  intraflagellar  transport  [45]. 
Finally, Alström and Cohen syndromes [41,42] are asso­
ciated with childhood truncal obesity and have a unique 
genetic  cause.  For  Alström  syndrome,  children  usually 
have normal birth weight but become obese during their 
first  year,  resulting  in  childhood  truncal  obesity  [41]. 
ALMS1, the only gene currently known to be associated 
with Alström syndrome [41], codes for a protein involved 
in the normal functioning of primary cilia. The only gene 
so far involved in Cohen syndrome is COH1, which encodes 
a transmembrane protein of unknown function [42].
Polygenic forms of early-onset obesity: early 
studies
Linkage studies
Genome­wide  linkage  scans  involve  the  genotyping  of 
families  using  highly  polymorphic  markers  that  are 
positioned  across  the  whole  genome,  followed  by  a 
calculation of the degree of linkage of the marker to a 
disease trait. Genome­wide linkage approaches led to the 
successful identification of numerous genes involved in 
Mendelian  human  diseases,  but  their  relevance  in  the 
identification of genes contributing to complex diseases 
has been more controversial [46]. More than 60 linkage 
studies  for  obesity­related  traits  were  published  in  the 
2006  update  of  the  Obesity  Map  [47],  but  only  three 
studies involved pedigrees with children or adolescents 
[48­50].
The only significant evidence of linkage for childhood 
obesity was obtained on chromosome 6q22.31­q23.2 in 
115 French pedigrees [49]. Subsequent positional cloning 
led to the identification of a three­allele risk haplotype 
(K121Q, IVS20delT­11, A→G +1044TGA; abbreviated to 
QdelTG)  in  the  ectonucleotide  pyrophosphatase/phos­
pho  diesterase 1 (ENPP1) gene that showed association 
with  childhood  obesity  and  contributed  in  part  to  the 
observed  linkage  of  chromosome  6q  with  childhood 
obesity [51]. The haplotype was associated with increased 
serum levels of soluble ENPP1 protein in children. The 
function of the gene can be directly related to obesity: 
ENPP1 inhibits insulin receptor activity [52], and up­ or 
downregulation  of  ENPP1  expression  in  liver  is  asso­
ciated  with  decreased  or  enhanced  insulin  sensitivity, 
respec  tively,  in  rodents  [53,54].  Insulin  resistance  in 
children  is  a  strong  predictor  of  future  weight  gain 
[55,56]. The association of the ENPP1 risk haplotype with 
childhood obesity has so far been replicated in only one 
(Bottcher  et  al.)  of  two  studies  [57,58],  and  further 
replication studies followed by a large meta­analysis are 
needed  to  provide  an  unequivocal  confirmation.  As 
observed for other complex diseases, linkage approaches 
have been mostly unsuccessful in identifying new obesity 
genes.  Statistical  simulations  predict  that  odds  ratios 
(ORs) must be high (more than 2) to induce significant 
peaks of linkage in modest family sample sets, making 
genome­wide linkage scans more relevant to identifying 
gene variants with high ORs [59].
Candidate gene association studies
Candidate  gene  approaches  have  been  performed  for 
hundreds of genes, and genetic variations in at least 127 
candidates have been associated with obesity in at least 
one study according to the 2006 update of the Human 
Obesity Map [47]. However, the risk of reporting a false 
positive result is extremely high in single underpowered 
studies  as  a  result  of  the  ‘winner’s  curse’  effect  (the 
‘winner’s curse’ effect leads to an over­representation of 
genetic studies with positive results in the literature), and 
only  three  genes  have  reached  a  convincing  level  of 
association with childhood and adult obesity using meta­
analytic strategies. Two coding non­synonymous gain­of­
function  polymorphisms  (V103I  and  I251L)  in  MC4R 
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obesity  onset  in  both  children  and  adults.  A  meta­
analysis of 15 independent studies was performed for the 
I251L polymorphism (OR = 0.38 to 0.71, P = 3 × 10­5), 
and 37 independent studies were collected for the study 
of  the  V103I  polymorphism  (OR  =  0.71  to  0.88, 
P < 0.0001) [60,61]. More recently, the non­synonymous 
variants  N221D  and  the  Q665E­S690T  cluster  in  the 
PCSK1 gene were consistently associated with obesity in 
adults and children in eight independent case­control or 
family­based cohorts of European ancestry (Poverall = 7 × 10­8 
and  Poverall  =  2  ×  10­12,  respectively)  [62].  Functional 
analysis showed a 10.4% reduction of the N221D­mutant 
PC1/3 protein catalytic activity [62]. The association of 
the N221D variant with BMI and obesity was confirmed 
in two large adult European populations [63,64]. MC4R 
and  PCSK1  can  be  considered  as  relevant  candidate 
genes  for  polygenic  studies  because  these  two  genes 
contribute  to  monogenic  forms  of  early­onset  obesity 
[65­67]. As the endocannabinoid receptor 1 (CNR1) is 
the target of the anti­obesity drug Accomplia, a candidate 
gene approach was performed with the CNR1 gene and 
led to the identification of two intronic polymorphisms 
(rs806381  and  rs2023239)  that  were  consistently 
associated with BMI level and childhood or adult obesity 
risk in a meta­analysis of 5,750 people [68]. Five indepen­
dent  studies  in  adults  confirmed  the  potential  role  of 
poly  morphisms  at  the  CNR1  locus  in  body­weight 
control [69­73].
Recent genomic research
The genome-wide association study revolution
The  dramatic  progress  in  the  human  genome  single 
nucleo  tide  polymorphism  (SNP)  map  through  the 
International HapMap Consortium [74], combined with 
the  development  of  new  methods  for  high­throughput 
genotyping using SNP microarrays, have made compre­
hen  sive  genome­wide  association  studies  (GWASs) 
possible  [75].  In  the  past  3  years,  genome­wide  asso­
ciation studies have led to the identification of more than 
250  genetic  loci  that  are  reproducibly  associated  with 
complex disease­related traits [76], including several loci 
associated with obesity risk and BMI variation [77].
The first GWAS for early­onset obesity was published 
in 2007 [78]. DNA array information was available for 
487  extremely  obese  young  German  people  and  442 
healthy  lean  German  controls,  and  replication  studies 
were performed with 644 independent families with at 
least  one  offspring  and  both  parents  obese  [78].  This 
modestly  powered  but  pioneering  study  identified 
variation in the Fat mass and obesity associated (FTO) 
gene as consistently associated with early­onset obesity 
and confirmed FTO as a major contributor to polygenic 
obesity ­ FTO had previously been linked by GWAS or 
population structure approaches to type 2 diabetes and 
obesity susceptibility [79­81].
In 2009, a GWAS was published for early­onset and 
morbid adult obesity in a French population. DNA arrays 
were  genotyped  in  685  obese  children,  695  morbidly 
obese adults (obese patients were from families with a 
high recurrence of obesity), 685 lean children and 731 
lean  adults.  The  best  association  signals  were  further 
investigated in 14,186 European adults or children [82]. 
This study independently confirmed at the genome­wide 
level of significance the association of variants in FTO 
and  near  MC4R  with  obesity  risk  and  BMI  variation 
(Poverall  for  obesity  risk  and  BMI  variation  =  1  ×  10­28  and  5  ×  10­15, 
respectively). The association signal near MC4R has been 
previously identified in a GWAS meta­analysis for BMI 
in European adults [83] and in a GWAS for waist circum­
ference in Asian Indians [84]. Three new obesity­predis­
posing loci (Niemann­Pick disease, type C1 (NPC1), the 
transcription  factor  c­MAF  (MAF)  and  phospho  tri­
esterase­related (PTER)) were identified at the genome­
wide level of significance in the whole sample [82].
Very recently, a joint analysis of GWAS for early­onset 
extreme  obesity  in  French  and  German  study  groups 
identified gene variants in or near FTO, MC4R, trans­
membrane protein 18 (TMEM18), serologically defined 
colon cancer antigen 8 (SDCCAG8) and TRF1­interacting 
ankyrin­related  ADP­ribose  polymerase/methionine 
sulfoxide  reductase  A  (the  TNKS/MSRA  gene  cluster) 
[85].  The  TMEM18  locus  was  previously  identified  as 
associated with adult BMI in the international GIANT 
consortium [64], and the TNKS/MSRA gene cluster had 
previously been linked to waist circumference in adults 
[86]. Interestingly, some of the new loci associated with 
BMI  in  adults  and  identified  by  GWAS  approaches 
[64,80,83,87] have also been associated with childhood 
extreme  obesity  (TMEM18,  Glucosamine­6­phosphate 
deaminase 2 (GNPDA2) and Neuronal growth regulator 1 
(NEGR1))  or  BMI  in  children  (Insulin  induced  gene  2 
(INSIG2),  FTO,  MC4R,  TMEM18,  GNPDA2,  NEGR1, 
BDNF,  and  Potassium  channel  tetramerization  domain 
containing  15  (KCTD15))  [64,88].  Several  of  the  likely 
causal obesity­predisposing genes are highly expressed or 
known to act in the central nervous system, emphasizing, 
as with Mendelian forms of obesity, a key role for central 
regulation  of  food  intake  in  predisposition  to  obesity 
[64].
Genome structural variation and early-onset obesity
Humans are usually diploid and they have two copies of 
each autosomal region, one per chromosome. This may 
differ  for  particular  genetic  regions  as  a  result  of 
structural  variation,  such  as  copy  number  variation 
(CNV), which includes deletion, duplication, transloca­
tion  and  inversion  of  chromosomes.  CNVs  are  either 
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been  suggested  that  common  CNVs  could  explain  a 
substantial part of heritability in complex diseases [89]. A 
common  45­kb  deletion  upstream  of  the  NEGR1  gene 
tagged by the polymorphism rs2815752 has been identi­
fied  as  associated  with  BMI  variation  in  adults  by  a 
GWAS  approach  [64].  This  deletion  was  consistently 
associated  with  BMI  variation  and  risk  for  extreme 
obesity in children [64,88].
Two reports have recently highlighted the contribution 
of rare CNVs to the genetic architecture of early­onset 
obesity [90,91]. A recent study including 300 Caucasians 
with severe early­onset obesity (143 of whom also had 
developmental  delay)  and  7,366  controls  showed  that 
large, rare chromosomal deletions (located on chromo­
somes 3, 6, 8, 10, 11, 15, 16, 17 and 22) were twice as 
frequent in patients as in controls [90]. A 16p11.2 dele­
tion  previously  associated  with  autism  [92,93],  schizo­
phrenia [94] or mental retardation [95] was carried by 
five patients with severe early­onset obesity and develop­
mental delays and was the commonest CNV associated 
with obesity [90]. The association between deletions on 
chromosome  16p11.2  and  obesity  and  developmental 
delays was confirmed in a second study involving more 
than  16,000  people  [91].  The  presence  of  deletions  at 
16p11.2  led  to  an  incomplete  penetrance  of  obesity  in 
childhood but to a fully penetrant phenotype of severe 
obesity in adulthood in this study [91]. In the two studies 
[90,91], 16p11.2 deletions arose de novo in some patients 
whereas they were inherited in others. The 16p11.2 dele­
tions accounted for 0.7% of morbid obesity cases without 
developmental  features  and  were  the  second  most 
frequent genetic cause of obesity after point mutations in 
MC4R  [91].  An  inverse  phenotype  of  underweight  has 
been observed in carriers of duplications on chromosome 
16p11.2,  confirming  a  key  role  of  this  region  in  body 
weight regulation [96].
CNV analysis has enabled detection of chromosomal 
regions (including a single gene or a contiguous set of 
genes) associated with obesity and thus the identification 
of new candidate genes implicated in disease suscepti­
bility.  The  16p11.2  deletion  interval  identified  in  these 
studies  encompasses  about  30  genes.  SH2B  adapter 
protein 1 (SH2B1) is one of these genes and is an excellent 
candidate  gene  to  link  the  16p11.2  deletion  to  obesity 
because its encodes a Janus kinase 2 (JAK2)­interacting 
protein that has been recently proposed as an endoge­
nous  enhancer  of  leptin  sensitivity  [97].  Disruption  of 
SH2B1  in  mice  induces  severe  hyperphagia,  obesity, 
severe insulin resistance and hyperleptinemia [97]. Inver­
sely,  neuron­specific  overexpression  of  SH2B1  in  mice 
protects against the leptin resistance and obesity that are 
induced by a high­fat diet [98]. In accordance with the 
phenotype observed in SH2B1­deficient mice, Bochukova 
and  colleagues  observed  that  carriers  of  the  16p11.2 
deletion,  in  addition  to  obesity,  exhibited  hyperphagia 
and  severe  insulin  resistance  disproportionate  to  the 
degree of obesity [90]. Several GWASs have reproducibly 
identified  SH2B1  as  a  risk  locus  for  common  obesity 
[64,87]. These data suggest a key role of the SH2B1 gene 
in the 16p11.2 deletion­related obesity phenotype, even if 
we  cannot  exclude  a  role  for  additional  genes  in  the 
deleted interval.
Gene-environment interactions
Environmental factors, such as diet, physical activity, age, 
gender,  socio­economic  status  and  ethnicity,  among 
others, have been shown to modulate the risk for obesity 
[20].  As  obesity  genetics  makes  further  progress,  con­
sider  able  interest  has  recently  been  turned  to  the 
potential interactions between obesity­predisposing gene 
variants and specific environmental situations. A signifi­
cant interaction between the effects of high­fat diet and 
FTO genotype on BMI has been reported recently, the 
observed increase in BMI across FTO genotypes being 
restricted to people who reported a high­fat diet [99]. An 
interaction  between  the  Apolipoprotein  A­II  (APOA2) 
­265T>C SNP and high saturated fat in relation to BMI 
and  obesity  has  been  observed  in  three  independent 
populations [100]. This SNP was not identified by recent 
GWAS  approaches,  suggesting  that  some  associations 
restricted  to  specific  environments  can  be  missed  in 
analyses  that  do  not  take  into  account  the  modifying 
effect of environmental co­variables.
An interaction between the FTO obesity risk genotype 
and physical activity on BMI variation or obesity risk has 
been consistently reported in nine independent studies 
including  adults  and  adolescents  [99,101­108].  These 
results strongly suggest that the increased risk of obesity 
provided  by  FTO  variants  can  be  attenuated  through 
physical activity.
Age  and  gender  can  be  viewed  as  specific  environ­
mental conditions. Age­dependent associations of gene 
variants  have  been  reported:  the  genetic  influence  of 
obesity  risk  common  variants  in  FTO  was  shown  to 
become  progressively  stronger  across  lifespan  [26,109], 
whereas gene variation in PCSK1 had more pronounced 
effects on BMI level and obesity risk in young than in late 
adulthood [63]. An age­dependent penetrance of MC4R 
pathogenic  mutations  on  obesity  has  been  found  in 
multigenerational pedigrees, the effect of mutations on 
the obesity phenotype being amplified by the develop­
ment of an ‘obesogenic’ environment [110].
Females are at higher risk of developing extreme forms 
of  obesity  than  males.  These  discrepancies  could  be 
explained,  at  least  in  part,  by  female­specific  genetic 
asso  ciations or by stronger effect sizes of genetic variants 
in  females.  This  was  observed  for  the  functional 
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member 1 (TBC1D1) gene. The effect of this variant on 
severe  obesity  risk  was  restricted  to  females  in  two 
independent populations [111,112]. The observed effect 
of MC4R pathogenic mutations on BMI was about twice 
as  strong  in  females  as  in  males  in  two  independent 
populations [110,113].
The well­established negative association between BMI 
and  educational  status  was  not  found  in  MC4R  loss­of 
function mutation carriers, although a significant relation­
ship  was  seen  in  MC4R  non­mutation  carriers  of  the 
corresponding pedigrees [110]. These results suggest that a 
high level of education has no protective effect on obesity 
risk in the presence of MC4R pathogenic mutations.
Recently,  the  first  evidence  of  ethnic­group­specific 
association with obesity has been reported. Variants in 
intronic regions of SIM1 were strongly associated with 
BMI and obesity risk (P = 4 × 10­7) in Pima Indians. The 
SNPs showing strongest association were genotyped in 
French individuals but no association with obesity was 
found  [114].  As  linkage  disequilibrium  blocks  (linkage 
disequilibrium  is  the  non­random  association  between 
alleles at different loci) can vary according to the ethnic 
background, an approach involving tagging of the SIM1 
locus was applied in French Europeans and excluded a 
major contribution of SIM1 common variants in poly­
genic  obesity  susceptibility,  a  result  confirmed  by  the 
absence  of  genome­wide  significant  association  in  the 
SIM1 gene region in recent GWASs [115]. Together, the 
studies  reviewed  in  this  section  highlight  the  complex 
interplay  between  genetic  susceptibility  to  obesity  and 
the experienced environment.
Genomics of early-onset obesity
The transcriptome
Differences in the adipose tissue transcriptome have been 
observed  depending  on  obesity  status  [116].  A  28­day 
very low calorie diet in obese patients induced changes in 
the  adipose  tissue  transcriptome  that  render  their 
expression  pattern  closer  to  the  profile  of  lean  people 
[117].  A  7­day  hypercaloric  diet  induced  significant 
differ  ences  in  the  adipose  tissue  expression  pattern  in 
both  lean  and  obese  people.  However,  six  genes  were 
differently expressed in response to overfeeding only in 
lean  people,  suggesting  that  there  is  a  protective 
mechanism  at  the  molecular  level  in  response  to  an 
energy surplus that is lacking in obese patients [118].
A recent study [119] assessed the impact of food intake 
on gene expression in human peripheral blood. Leonard­
son  and  colleagues  [119]  found  that  gene­expression 
variations are strongly connected to clinical traits related 
to obesity, such as hip circumference, but depend on the 
nutritional  state  (fasted  or  fed).  The  response  to  food 
intake  has  a  significant  genetic  component  and  could 
facilitate  the  dissection  of  the  underlying  causes  of 
obesity. The composition of the diet can also modulate 
gene expression. High­fat versus low­fat diets have been 
associated with changes in the hypothalamic transcrip­
tome  of  mice  [120].  Beyond  the  simple  observation  of 
changes in transcriptome according to disease status or 
diet  interventions,  adipose  gene  expression  signatures 
may help differentiate responders from non­responders 
to low­fat hypocaloric diet and pave the way for future 
personalized nutritional approaches [121].
Testing  DNA  markers  for  association  with  complex 
traits at the genome­wide scale is now a reality. However, 
more  information  on  how  variations  in  DNA  affect 
complex physiological processes may come from trans­
criptome studies [122]. Gene expression can be used as 
an intermediary phenotype for complex traits in order to 
refine the disease phenotype and identify pathways and 
genes associated with that disease phenotype [123]. By 
integrating DNA variation and gene expression data in 
liver (an important tissue involved in metabolic diseases) 
with  the  complex  trait  obesity  in  segregating  mouse 
populations, and by validating the best candidate genes 
in  knock­out  or  transgenic  mice,  Eric  Schadt  and 
colleagues [123­126] identified ten causal genes involved 
in  variation  of  obesity­associated  traits.  An  integrative 
approach  combining  gene  expression  adipose  data  in 
humans and mice, genome­wide linkage and association 
mapping and a gene network approach [127] identified a 
core network module of genes involved in the inflamma­
tory  and  immune  response  as  causally  associated  with 
obesity­related traits. Although this study [127] did not 
provide further functional support for candidate obesity­
susceptibility  genes,  the  expression  quantitative  trait 
locus approach in well targeted tissues is promising and 
may  contribute  to  increasing  the  list  of  causal  genes 
involved in human obesity in the near future.
The gut microbiome
The  gut  microbiota  can  be  considered  as  an  environ­
mental factor that regulates fat storage [128]. Significant 
alterations in the composition of the intestinal microbiota 
have  been  identified  in  obese  mice,  suggesting  that 
differences in intestinal flora may explain some of the risk 
for  obesity  [129].  The  proportion  of  beneficial  Bacter­
oidetes bacteria is lower in obese adult patients than in 
lean  counterparts,  and  this  proportion  increases  with 
weight loss induced by a low calorie diet [130]. Whereas 
individuals from the same families had a closer bacterial 
community  structure  than  unrelated  individuals,  a 
comparable  degree  of  co­variation  was  found  between 
adult monozygotic and dizygotic twin pairs, suggesting 
that  the  gut  microbiome  does  not  have  a  heritable 
component but is strongly influenced by the environment 
[131].  A  case­control  study  in  Indian  children  [132] 
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bacterium  prausnitzii  in  obese  versus  lean  children. 
Another study conducted with children [133] found that 
aberrant  intestinal  flora  enriched  in  Staphylococcus 
aureus precedes the development of overweight later in 
childhood and could be used as a biomarker for the early 
evaluation  of  the  predisposition  to  obesity.  A  recently 
published  human  gut  microbial  catalog  of  3.3  million 
non­redundant  microbial  genes  [134]  will  help  assess 
with  greater  accuracy  the  impact  of  metagenome 
diversity on obesity in humans.
Prospects for prediction, prevention and 
personalized medicine
Agnostic genome­wide approaches have illuminated un­
expected biological pathways and provided a useful list of 
new  candidate  genes  for  further  exploration  [76]. 
However,  the  use  of  genetic  information  to  predict 
individual risk of disease in clinical practice remains the 
‘Holy Grail’ for many geneticists [135]. Common variants 
recently identified by GWASs have a limited predictive 
value for obesity risk [136,137]. International consortia 
are  currently  working  to  increase  the  list  of  validated 
obesity­predisposing  SNPs,  and  sophisticated  method­
olo  gies (such as machine­learning approaches) are emerg­
ing to make better use of SNP information con  tained in 
DNA  arrays  for  disease  prediction  [138].  However,  it  is 
likely that common variation will explain only a modest 
fraction of heritability for early­onset obesity (for example 
FTO, the strongest predictor of obesity, is responsible for 
only 1% of the total heritability) [139].
These results re­emphasize the importance of mono­
genic  obesity  in  elucidating  the  heritability  of  obesity 
because  rare  deleterious  mutations  in  the  eight  well­
established monogenic obesity genes (LEP, LEPR, POMC, 
PCSK1, MC4R, BDNF, SIM1 and NTRK2) could explain 
up  to  10%  of  cases  with  early­onset  extreme  obesity. 
Mutations in these single genes are sufficient by them­
selves  to  cause  a  strong  effect  on  phenotype.  People 
carrying  these  mutations  have  severe  hyperphagia  and 
early­onset obesity but also some other specific features 
(such as a low level of circulating leptin despite severe 
obesity, a susceptibility to infections, intestinal dysfunc­
tion, reactive hypoglycemia, red hair and pale skin and 
adrenal  insufficiency)  that  can  guide  gene  sequencing 
approaches (Figure 1).
Figure 1. Monogenic gene screening prioritization during clinical examination. Early-onset obesity and hyperphagia are general features of 
monogenic obesity. Additional and more specific features can be useful to prioritize which gene should be sequenced first.
Specific features Gene to sequence first
LEP
LEP, LEPR
LEP, LEPR
POMC
POMC
POMC, PCSK1
PCSK1
MC4R
SIM1, BDNF, NTRK2
General features
LEP, LEPR,
POMC, PCSK1, 
MC4R, SIM1, 
BDNF, NTRK2
Low level of circulating leptin
High rate of childhood infections
Hypothyroidism
Hypoadrenalism, jaundice
Pale skin, red hair
Hypoglycemia
Intestinal dysfunction
High/Tall stature
Developmental delays
Early-onset obesity
Hyperphagia
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tion  and  effective  therapeutic  management.  The  most 
effective preventive strategy for these monogenic muta­
tion carriers may be stringent restriction of food access. 
This will require the training and active participation of 
the parents. Beyond the eight currently known genes, the 
high  occurrence  of  Mendelian  patterns  of  inheritance 
observed  in  multigenerational  pedigrees  with  extreme 
obesity together with the large fraction of unexplained 
‘missing’  heritability  [139]  suggests  that  the  causes  of 
many monogenic cases remain to be elucidated [140].
Several innovative strategies may soon lead to a more 
exhaustive picture of monogenic obesity. High­resolution 
homozygosity  mapping  in  large  consanguineous 
pedigrees  is  a  powerful  approach  to  discovering  new 
obesity  loci  with  a  recessive  mode  of  inheritance,  as 
recently exemplified by syndromic forms of obesity [141]. 
Full  exome  capture  (an  efficient  strategy  to  selectively 
sequence the coding regions of the human genome) and 
parallel  sequencing  strategies  in  carefully  selected 
unrelated cases and controls have proven successful for 
gene  identification  [142],  and  this  approach  should  be 
successfully  extended  in  the  future  to  pedigrees  with 
extreme obesity and a Mendelian pattern of inheritance. 
Genome­wide studies of structural variation in pedigrees 
or  large  case­control  series  followed  by  a  systematic 
resequencing  approach  for  genes  located  in  genome 
structural  variation  intervals  may  help  to  identify 
additional Mendelian obesity genes.
Apart  from  Mendelian  forms  of  obesity,  the  use  of 
genetic  information  alone  will  provide  only  limited 
predictive value in classifying young people at high risk 
for the development of childhood obesity. As summar­
ized  here,  additional  factors,  such  as  environmental 
conditions, the transcriptome, the epigenome and the gut 
metagenome,  can  affect  future  obesity  or  response  to 
dietary  interventions.  Further  work  is  now  needed  to 
achieve a successful integration of all these sources of data 
to enable us to identify young people at risk for obesity and 
personalize preventive strategies (Figure 2) [143].
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